argenx heads into its third-quarter report with a curious split screen. The business has just posted what management called one of its strongest quarters yet, extending an 18-quarter streak of growth and turning a newly approved seronegative myasthenia gravis indication into a live launch. The stock, however, has gone the other way, sliding about 8% since the last report while the S&P 500 gained roughly 5%. The October 22 release, due before the opening bell, is a test of whether the commercial engine can keep compounding fast enough to win back a market that has grown cautious.

Wall Street expects earnings of $7.44 a share on revenue of about $1.66 billion, which would be growth of roughly 44% on both lines versus the year-ago quarter. That is still exceptional for a company of this size, but it marks a visible slowdown from the 60% revenue growth posted in the second quarter, largely because the comparison base stepped up sharply in late 2025. Sequentially, the Street is asking for revenue to rise about 8% from $1.54 billion. That bar is a bit higher than it looks: second-quarter sales included a roughly $25 million one-time benefit in Japan tied to a change in its distribution model, so the underlying climb required is closer to 10%. Meanwhile, consensus EPS sits only modestly above last quarter's $7.32, suggesting analysts already expect spending to absorb much of the incremental revenue.

The seronegative launch is the main thread to pull. Management said coverage reached about 55% of US commercial lives within ten weeks and that most payers had dropped serology testing requirements, while also describing a halo effect lifting prescriptions among seropositive patients. Validation would look like another strong sequential gain in US sales, which rose 15% last quarter to about $1.3 billion, along with evidence that coverage has broadened and that new patients are converting into durable, repeat therapy. The prefilled syringe matters here too, since roughly 80% of second-quarter syringe patients were new to the brand. If US growth flattens or management leans heavily on inventory or one-time items to explain the quarter, the case that seronegative patients represent a genuine step-change in the addressable market would weaken.

Margins are the second swing factor. Operating profit jumped to $494 million last quarter, up 146% year over year, and management has framed expanding margins as a core part of the story. But total operating expenses reached about $1 billion, up $129 million from the prior quarter, as the company funds launches, a broad pipeline and a planned 2027 auto-injector rollout. A quarter in which revenue grows and operating profit barely moves would raise questions about how much leverage is really left. Updates on business development also deserve attention, since management widened its ambitions to include biotech acquisitions on the back of a $5.2 billion cash pile.

Pipeline news may color the reaction as much as the numbers. Management had pointed to a registrational myositis readout in the third quarter and an MMN readout for impasitoprubat before year-end, while continuing to prune programs, most recently dropping delayed graft function. It also cautioned that the dermatomyositis subgroup is heterogeneous and that statistical success was not assured.

Sentiment has warmed from clearly bearish a quarter ago to roughly neutral, yet the stock trades below its 200-day moving average near $852 and sits only about 2% above the low of its post-earnings range, far beneath a peak above $1,070. That positioning means expectations are hardly euphoric. The central question is simple: can argenx show that seronegative demand and syringe adoption are driving clean, underlying US acceleration that outpaces its swelling cost base? If so, the growth narrative remains intact and the stock's discount looks hard to justify.